Search the site

The six-minute tests that could save lives

Thanks to research, a six -second test can get the answers that could save a child’s life.

Major grant empowers community voices to drive reduction in skin infections

Aboriginal community members throughout the Kimberley will take a lead role in driving healthy skin messages within their own communities thanks to a major funding boost to The Kids Research Institute Australia’s SToP Trial.

End Rheumatic Heart Disease Centre of Research Excellence

The END RHD CRE is producing a costed, step-wise strategy to end rheumatic heart disease (RHD) as public health priority in Australia.

Functional differences in airway dendritic cells determine susceptibility to IgE-sensitization

Respiratory IgE-sensitization to innocuous antigens increases the risk for developing diseases such as allergic asthma.

Route of exposure alters inflammation and lung function responses to diesel exhaust

In this study, we compared the physiological consequences of short-term exposure to diesel exhaust via inhalation to those due to exposure to the same diesel...

Sensitizing and Th2 Adjuvant Activity of Cysteine Protease Allergens

Here, we report on a model that does not use Th2-skewing adjuvants and yet achieves sensitization solely via the nasal mucosa.

Australia’s first regenerative and genetic medicine program for children’s lung disease

A new program that uses cutting edge stem cell techniques to repair lung damage in children will be established at The Kids Research Institute Australia with support from the Telethon-Perth Children’s Hospital Research Fund (TPCHRF).

Biobank funding supports valuable research resources

Four The Kids Research Institute Australia-based biobanks which underpin a range of cancer, respiratory and early life research have received more than $450,000 in funding.

Enhancing the lung health for preterm birth survivors by uncovering treatable traits

A project to uncover treatable traits to improve the lung health of people born preterm has been made possible thanks to a $1.99 million Medical Research Future Fund (MRFF) grant.

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.